Myogen, Inc.

Myogen is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapeutics for the treatment of cardiovascular disorders. We believe that our advanced understanding of the biology of cardiovascular disease combined with our clinical development expertise in cardiovascular therapeutics provide us with the capability to discover novel therapies, as well as identify, license or acquire products that address serious, debilitating cardiovascular disorders that are not adequately treated with existing therapies.We have two product candidates in late-stage clinical development: ambrisentan for the treatment of pulmonary arterial hypertension (PAH) and darusentan for the treatment of resistant hypertension (RHTN). Myogen, in partnership with Novartis, also conducts a target and drug discovery research program focused on the development of disease-modifying drugs for the treatment of chronic heart failure and related cardiovascular disorders.

Contact Details: 7575 W. 103rd Avenue, Suite 102 Westminster Colorado 80021-5426 United States of America Tel: 303-410-6666 Fax: 303-410-6667 Email: IR@myogen.com WWW: www.myogen.com/

Loading...

BioNews Results for Myogen, Inc.:
Bioscience group names award recipients	Boulder County Business Report:  Nov 6 2009 3:10AM Matching: myogen inc

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 364 times since April 2007, the link to the organisation's website has been followed 57 times

Search for more companies in Westminster

Search for more companies in Colorado

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Myogen, Inc.